Lung cancer
Disease3 papers2 findings
- Humans1
- Animals1
Interventions
1Rapamycin + doxorubicin
downin mice1
1 study
Rapamycin + doxorubicin
downin mice1
Rapamycin + doxorubicin decreases lung cancer in mice.
Animalschemoresistant lung cancer modelL1CAM aptamer-modified DPPC nanoliposomeslung
Inhalable nanoliposomes target senescence and overcome chemoresistance in mouse lung cancer · Biomaterials · 23 Sep 2026
Associations
1ASXL1 mutation
upin humans1
1 study
ASXL1 mutation
upin humans1
ASXL1 mutation raises the risk of lung cancer in humans (hazard ratio = 3.2).
Humanshigh variant allele fraction (high-VAF), adjusted for age, sex, BMI, smoking status, and genetic ancestry
Clonal blood mutations in ASXL1 associate with higher lung cancer risk · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 28 Sep 2026
Latest
3Inhalable nanoliposomes target senescence and overcome chemoresistance in mouse lung cancer
The formulation co-delivers rapamycin and doxorubicin across the mucus barrier to inhibit mTOR and suppress tumor growth without evident systemic toxicity.
Clonal blood mutations in ASXL1 associate with higher lung cancer risk
Researchers analyzing two large human cohorts found that ASXL1-mutant clonal hematopoiesis linked to more than triple the risk of lung cancer in smokers.